How Can New Myeloma Treatments Play a Role When Maintenance Therapy Becomes Ineffective?
Myeloma expert Dr. Robert Orlowski answers more Ask the Expert questions, this one from Susan: “What effect will newly approved drugs, such as daratumamab and ixazomib have on a patient when Revlimid ...
Author: P2Professional
Added: 02/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 4, 2016 Category: Cancer & Oncology Source Type: podcasts
How Can New Myeloma Treatments Play a Role When Maintenance Therapy Becomes Ineffective?
Myeloma expert Dr. Robert Orlowski answers more Ask the Expert questions, this one from Susan: “What effect will newly approved drugs, such as daratumamab and ixazomib have on a patient when Revlimid ...
Author: patientpower
Added: 02/02/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 3, 2016 Category: Cancer & Oncology Source Type: podcasts
ASH 2015: Eloquent-2 Update
Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Effica...
Author: InternationalMyelomaFoundation
Added: 12/08/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 8, 2015 Category: Cancer & Oncology Source Type: podcasts
iwNHL 2015: Therapeutic opportunities for lenalidomide in non-Hodgkin lymphoma
At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Nathan H. Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing clinical tria...
Author: VJHemOnc
Added: 11/22/2015 (Source: Oncology Tube)
Source: Oncology Tube - November 23, 2015 Category: Cancer & Oncology Source Type: podcasts
Day 2 highlights of the International Workshop on Non-Hodgkin Lymphoma 2015 meeting: Lenalidomide and ibrutinib for diffuse large B-cell lymphoma
John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, ...
Author: VJHemOnc
Added: 11/18/2015 (Source: Oncology Tube)
Source: Oncology Tube - November 18, 2015 Category: Cancer & Oncology Source Type: podcasts
ASCO 2014: A phase 1 trial of MK-3475 combined with Len and Lo-dose Dex in patients with RRMM
David Siegel, MD
John Theurer Cancer Center
Hackensack, New Jersey, USA
A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with r...
Author: InternationalMyelomaFoundation
Added: 09/11/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 11, 2015 Category: Cancer & Oncology Source Type: podcasts
ASCO 2014: A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in RRMM
David Siegel, MD
John Theurer Cancer Center
Hackensack, New Jersey, USA
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple m...
Author: InternationalMyelomaFoundation
Added: 09/11/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 11, 2015 Category: Cancer & Oncology Source Type: podcasts
ASCO 2014: MM-027 trial
Saad Z. Usmani, MD
Levine Cancer Institute - Morehead
Charlotte, North Carolina, USA
Continuous lenalidomide (LEN) therapy versus observation following nonimmunomodulatory compound-based inductio...
Author: InternationalMyelomaFoundation
Added: 09/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 10, 2015 Category: Cancer & Oncology Source Type: podcasts
ASCO 2014: A phase Ib dose escalation trial of SAR650984 in combination with len/dex in RR MM
Thomas G. Martin, MD
University of California SF
San Francisco, California, USA
A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone i...
Author: InternationalMyelomaFoundation
Added: 09/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 10, 2015 Category: Cancer & Oncology Source Type: podcasts
ASCO2014: A Phase III trial Comparing MPT versus MPR In Newly Diagnosed Multiple Myeloma
Keith K. Stewart, MB ChB
Mayo Clinic
Scottsdale, Arizona, USA
E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) ...
Author: InternationalMyelomaFoundation
Added: 09/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 10, 2015 Category: Cancer & Oncology Source Type: podcasts
ELOQUENT-2: Lenalidomide and dexamethasone with or without elotuzumab in relapsed/refractory multiple myeloma | Dr Joseph Mikhael at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 3 ELOQUENT-2 trial of lenalidomide an...
Author: EMJ
Added: 07/20/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2015 Category: Cancer & Oncology Source Type: podcasts
EHA 2015: Lenalidomide in relapsed or refractory mantle cell lymphoma
Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, presents the results of a subgroup analysis of the phase 2 SPRINT trial at the 20th Congress of the European Hematology Associatio...
Author: VJHemOnc
Added: 07/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 10, 2015 Category: Cancer & Oncology Source Type: podcasts
ASCO 2015: Results of the ELOQUENT-2 trial of elotuzumab in multiple myeloma
At ASCO 2015, Dr Joseph Mikhael discusses the results of ELOQUENT-2, a phase 3, randomized, open-label trial of lenalidomide plus dexamethasone with or without elotuzumab in patients with relapsed or ...
Author: VJHemOnc
Added: 07/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 10, 2015 Category: Cancer & Oncology Source Type: podcasts
FIRST study: Continuous lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma
At the 20th Congress of the European Hematology Association (EHA), Thierry Facon, MD, of the University Hospital Hurriez, Lille, France, discusses the updated overall survival analysis of the FIRST st...
Author: VJHemOnc
Added: 07/01/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2015 Category: Cancer & Oncology Source Type: podcasts
Subgroup analysis of the phase 2 MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory mantle cell lymphoma | Prof Marek Trněný at EHA 2015
At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the results of the subgroup analysis of the phase 2 m...
Author: EMJ
Added: 06/29/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 29, 2015 Category: Cancer & Oncology Source Type: podcasts
